Peptide Comparison
Decapeptide-12 vs Pal-GHK
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Decapeptide-12 and Pal-GHK share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Pal-GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Pal-GHK's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Decapeptide-12 | Pal-GHK | |
|---|---|---|
| Class | Cosmetic peptide; tyrosinase inhibitor | Cosmetic lipopeptide (collagen) |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Competitive tyrosinase inhibition; reduces melanin synthesis | Palmitoyl-modified GHK for enhanced penetration; copper-independent collagen signaling |
| Route | Topical | Topical |
| Half-life | Topical | Topical |
| Dosage (research) | Topical 0.01-0.1% | Topical 1-3% |
| Evidence tier | Cosmetic Clinical Studies | Cosmetic Clinical Studies |
| Research depth | 18 indexed | 37 indexed |
| Availability | Cosmetic | Cosmetic |
| Reported risks | Minimal; slow visible results | Minimal |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Decapeptide-12 or Pal-GHK?
Decapeptide-12 and Pal-GHK share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Pal-GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Pal-GHK's evidence base is currently denser.
What is the difference between Decapeptide-12 and Pal-GHK?
Decapeptide-12 is classed as Cosmetic peptide; tyrosinase inhibitor; Pal-GHK is classed as Cosmetic lipopeptide (collagen). Reported mechanism: Decapeptide-12, Competitive tyrosinase inhibition; reduces melanin synthesis; Pal-GHK, Palmitoyl-modified GHK for enhanced penetration; copper-independent collagen signaling. Reported half-life: Decapeptide-12, Topical; Pal-GHK, Topical. Routes in published studies: Decapeptide-12, Topical; Pal-GHK, Topical.
Which has stronger evidence, Decapeptide-12 or Pal-GHK?
Decapeptide-12 and Pal-GHK sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Decapeptide-12 is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 18 indexed studies. Pal-GHK is graded Cosmetic Clinical Studies, with 5 cited sources on its reference page and 37 indexed studies.
Which is more accessible, Decapeptide-12 or Pal-GHK?
Neither Decapeptide-12 nor Pal-GHK is an FDA-approved drug. Catalog status: Decapeptide-12, Cosmetic; Pal-GHK, Cosmetic.
Are Decapeptide-12 and Pal-GHK ever combined?
Decapeptide-12 and Pal-GHK appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…